LegoChem Biosciences Inc
KOSDAQ:141080
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
47 100
140 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
LegoChem Biosciences Inc
Accrued Liabilities
LegoChem Biosciences Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Accrued Liabilities
₩11.4B
|
CAGR 3-Years
241%
|
CAGR 5-Years
112%
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Accrued Liabilities
₩338.5B
|
CAGR 3-Years
28%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
K
|
Knotus Co Ltd
KOSDAQ:278650
|
Accrued Liabilities
₩631.2m
|
CAGR 3-Years
22%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Accrued Liabilities
₩8.3B
|
CAGR 3-Years
66%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Accrued Liabilities
₩906.5m
|
CAGR 3-Years
114%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Accrued Liabilities
₩7.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
132%
|
CAGR 10-Years
N/A
|
|
LegoChem Biosciences Inc
Glance View
LegoChem Biosciences Inc., rooted in South Korea, is navigating the complex world of pharmaceutical innovation with a focus sharp enough to captivate both scientists and investors. Founded in 2006, the company has honed its expertise particularly in the field of antibody-drug conjugates (ADCs). This novel approach merges the targeting capabilities of antibodies with the cancer-killing prowess of chemotherapy drugs, aiming to deliver high precision in cancer treatment while minimizing side effects. LegoChem conducts meticulous research and development, advancing its proprietary ConjuAll™ technology platform, which enhances the stability and efficacy of ADCs. This dedication to scientific innovation underscores the company's strategy of robust collaboration and partnerships with global pharmaceutical giants, enabling it to leverage complementary expertise and expedite the commercialization of its cutting-edge therapies. LegoChem Biosciences generates revenue primarily through a strategic business model that revolves around licensing agreements and research collaborations with major pharmaceutical players. The company enters into partnerships where it licenses out its advanced drug discovery platforms, receiving upfront payments, milestones based on developmental progress, and royalties upon successful commercialization of its licensed products. These collaborative strategies not only finance ongoing research but also diversify revenue streams and mitigate the inherent financial risks associated with drug development. By focusing on areas with high unmet medical needs, LegoChem not only positions itself advantageously in the competitive biotech landscape but also aligns with a mission to transform lives through innovation. With a clear-eyed vision and strategic partnerships, LegoChem Biosciences Inc. continues its quest to make significant strides in the realm of targeted cancer therapies.
See Also
What is LegoChem Biosciences Inc's Accrued Liabilities?
Accrued Liabilities
11.4B
KRW
Based on the financial report for Sep 30, 2024, LegoChem Biosciences Inc's Accrued Liabilities amounts to 11.4B KRW.
What is LegoChem Biosciences Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
112%
Over the last year, the Accrued Liabilities growth was 1 344%. The average annual Accrued Liabilities growth rates for LegoChem Biosciences Inc have been 241% over the past three years , 112% over the past five years .
You don't have any saved screeners yet